Pathogenic, criteria provided, single submitter | research | Laboratório de Neurologia Aplicada e Experimental, Faculdade de Medicina de Ribeirao Preto – Universidade de Sao Paulo | Jul 20, 2021 | The variant p.Arg232Cys variant in the TRPV4 gene has been observed in several individuals with TRPV4-related disorders, including distal hereditary motor neuropathy type VIII (dHMN8), scapuloperoneal spinal muscular atrophy (SPSMA), and Charcot-Marie-Tooth disease type 2C (CMT2C). This variant is not present in population databases (GnomAD and ABraOM). ClinVar classifies this variant as Pathogenic (Variation ID: 30472), 2 stars (multiple consistent, 9 submissions), backed by functional studies (requires user validation) mentioned in 21288981, and also citing 8 articles (26948711, 26048687, 24789864, 22702953, 22526352 and 3 more). This variant replaces arginine with cysteine at codon 232 of the TRPV4 protein, which is highly conserved across different species. In summary, the p.Arg232Cys meets our criteria to be classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | - | The variant is not observed in the gnomAD v2.1.1 dataset. Missense changes are a common disease-causing mechanism. Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 21288981, 21288981). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.68; 3Cnet: 0.65). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000030472 / PMID: 20460441). The variant has been observed in multiple (>3) similarly affected unrelated individuals (PMID: 20460441, 21288981, 24789864). The variant has been reported to co-segregate with the disease in at least 3 similarly affected relatives/individuals in the same family or similarly affected unrelated families (PMID: 20460441, 21288981, 24789864). Different missense changes at the same codon (p.Arg232Pro, p.Arg232Ser) have been reported to be associated with TRPV4 related disorder (ClinVar ID: VCV001493962 / PMID: 24789864). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 31, 2012 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 13, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 232 of the TRPV4 protein (p.Arg232Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease type 2C, distal hereditary motor neuropathy, and/or scapuloperoneal spinal muscular atrophy (PMID: 20460441, 21288981, 22526352, 24789864, 26048687). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 30472). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on TRPV4 protein function. Experimental studies have shown that this missense change affects TRPV4 function (PMID: 21288981, 22702953). For these reasons, this variant has been classified as Pathogenic. - |